Biotech Values

[DewDiligence]

Ribavirin has weak but well-established efficacy as an HCV anti-replication agent; it typically produces a mean of ~0.8 logs of viral reduction when used as monotherapy. (Source: various CC’s from such companies as GILD, ANDS, VRUS, and IDIX.)